RayzeBio (RYZB) Stock Price, News & Analysis

Company Overview

RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California. As of February 26, 2024, RayzeBio, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

Key Stats

• Today's Range: $62.49 to $62.49
• 50-Day Range: $62.27 to $62.49
• 52-Week Range: $17.95 to $62.51
• Volume: N/A
• Average Volume: 553,592 shs
• Market Capitalization: $3.74 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RYZB Stock Analysis - Frequently Asked Questions

When did RayzeBio IPO?

RayzeBio (RYZB) raised $311 million in an initial public offering (IPO) on Friday, September 15th 2023. The company issued 17,277,600 shares at $18.00 per share.

What other stocks do shareholders of RayzeBio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that RayzeBio investors own include Apogee Therapeutics (APGE), Broadcom (AVGO), Citigroup (C), Citizens Financial Group (CFG), Cisco Systems (CSCO), Fifth Third Bancorp (FITB) and Intel (INTC).

Company Calendar

• Today: 9/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:RYZB
• CIK: 1825367
• Web: rayzebio.com
• Phone: 619-937-2754
• Fax: N/A
• Employees: 88
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 31.85
• Quick Ratio: 31.85

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 59,920,000
• Free Float: N/A
• Market Cap: $3.74 billion
• Optionable: Optionable
• Beta: N/A